- Home
- MIRA vs CCEL Comparison
MIRA vs CCEL Comparison
Compare MIRA & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CCEL
- Stock Information
- Founded
- MIRA 2020
- CCEL 1989
- Country
- MIRA United States
- CCEL United States
- Employees
- MIRA N/A
- CCEL N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- MIRA Health Care
- CCEL Health Care
- Exchange
- MIRA Nasdaq
- CCEL Nasdaq
- Market Cap
- MIRA 33.7M
- CCEL 35.8M
- IPO Year
- MIRA 2023
- CCEL 1997
- Fundamental
- Price
- MIRA $1.49
- CCEL $4.24
- Analyst Decision
- MIRA
- CCEL Hold
- Analyst Count
- MIRA 0
- CCEL 1
- Target Price
- MIRA N/A
- CCEL N/A
- AVG Volume (30 Days)
- MIRA 286.8K
- CCEL 4.2K
- Earning Date
- MIRA 11-13-2025
- CCEL 10-15-2025
- Dividend Yield
- MIRA N/A
- CCEL 9.85%
- EPS Growth
- MIRA N/A
- CCEL N/A
- EPS
- MIRA N/A
- CCEL N/A
- Revenue
- MIRA N/A
- CCEL $31,747,500.00
- Revenue This Year
- MIRA N/A
- CCEL $0.30
- Revenue Next Year
- MIRA N/A
- CCEL N/A
- P/E Ratio
- MIRA N/A
- CCEL N/A
- Revenue Growth
- MIRA N/A
- CCEL N/A
- 52 Week Low
- MIRA $0.73
- CCEL $4.00
- 52 Week High
- MIRA $2.45
- CCEL $9.10
- Technical
- Relative Strength Index (RSI)
- MIRA 52.64
- CCEL 48.63
- Support Level
- MIRA $1.33
- CCEL $4.04
- Resistance Level
- MIRA $1.45
- CCEL $4.45
- Average True Range (ATR)
- MIRA 0.09
- CCEL 0.12
- MACD
- MIRA -0.00
- CCEL 0.03
- Stochastic Oscillator
- MIRA 79.63
- CCEL 53.81
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.